Comparison of zotarolimus-eluting and sirolimus-eluting coronary stents: a study from the Western Denmark Heart Registry

BMC Cardiovascular Disorders

Leif Thuesen⁴  Jens Flensted Lassen⁴  Henrik Toft Sørensen²  Morten Madsen⁵  Per Thayssen¹  Evald Høj Christiansen⁴  Hans-Henrik Tilsted³  Anne Kaltoft⁴  Lisette Okkels Jensen¹  Michael Maeng⁴ 

[1] Department of Cardiology, Odense University Hospital, Odense, Denmark;Department of Epidemiology, Boston University, Boston, MA, USA;Department of Cardiology, Aarhus University Hospital, Aalborg Hospital, Aalborg, Denmark;Department of Cardiology, Aarhus University Hospital, Skejby, Brendstrupgaardsvej 100, 8200, Aarhus N, Denmark;Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark

关键词: Diabetes mellitus;    Stent thrombosis;    Mortality;    Stent;    Sirolimus;    Zotarolimus;   

Others  :  1084356
DOI  :  10.1186/1471-2261-12-84

 received in 2012-01-22, accepted in 2012-09-20,  发布年份 2012

【 摘 要 】

Background

We evaluated the effectiveness and safety of a zotarolimus-eluting (ZES) versus a sirolimus-eluting (SES) coronary stent in a large cohort of patients treated with one of these stents in Western Denmark.

Methods

A total of 6,122 patients treated with ZES (n=2,282) or SES (n=3,840) were followed for up to 27 months. We ascertained clinical outcomes based on national medical databases.

Results

Incidence of target lesion revascularization (no. per 100 person-years) was 5.3 in the ZES group compared to 1.9 in the SES group (adjusted hazard ratio (HR)=2.19, 95% confidence intervals (CI): 1.39-3.47; p=0.001). All-cause mortality was also higher in the ZES group (ZES: 6.3; SES: 3.3; adjusted HR=1.34, 95% CI: 1.05-1.72; p=0.02), while stent thrombosis (ZES: 1.2; SES: 0.5; adjusted HR=1.98, 95% CI: 0.75-5.23; p=0.14) did not differ significantly.

Conclusions

In agreement with previously published randomised data, this observational study indicated that the ZES was associated with an increased risk of death and TLR in a large cohort of consecutive patients.

【 授权许可】

   
2012 Maeng et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O’Shaughnessy C, et al.: Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003, 349:1315-1323.
• [2]Stone GW, Ellis SG, Cox DA, Hermiller J, O’Shaughnessy C, Mann JT, et al.: A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004, 350:221-231.
• [3]Kelbaek H, Klovgaard L, Helqvist S, Lassen JF, Krusell LR, Engstrom T, et al.: Long-term outcome in patients treated with sirolimus-eluting stents in complex coronary artery lesions: 3-year results of the SCANDSTENT (Stenting Coronary Arteries in Non-Stress/Benestent Disease) trial. J Am Coll Cardiol 2008, 51:2011-2016.
• [4]Kaltoft A, Jensen LO, Maeng M, Tilsted HH, Thayssen P, Bottcher M, et al.: Two-Year Clinical Outcomes after Implantation of Coronary Sirolimus- and Paclitaxel-eluting Stents and Bare Metal Stents in Western Denmark. J Am Coll Cardiol 2008, 53:658-664.
• [5]Mauri L, Silbaugh TS, Wolf RE, Zelevinsky K, Lovett A, Zhou Z, et al.: Long-term clinical outcomes after drug-eluting and bare-metal stenting in massachusetts. Circulation 2008, 118:1817-1827.
• [6]Tu JV, Bowen J, Chiu M, Ko DT, Austin PC, He Y, et al.: Effectiveness and safety of drug-eluting stents in Ontario. N Engl J Med 2007, 357:1393-1402.
• [7]Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, et al.: Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007, 369:667-678.
• [8]Cook S, Wenaweser P, Togni M, Billinger M, Morger C, Seiler C, et al.: Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation 2007, 115:2426-2434.
• [9]Finn AV, Nakazawa G, Joner M, Kolodgie FD, Mont EK, Gold HK, et al.: Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol 2007, 27:1500-1510.
• [10]Sakurai R, Hongo Y, Yamasaki M, Honda Y, Bonneau HN, Yock PG, et al.: Detailed intravascular ultrasound analysis of Zotarolimus-eluting phosphorylcholine-coated cobalt-chromium alloy stent in de novo coronary lesions (results from the ENDEAVOR II trial). Am J Cardiol 2007, 100:818-823.
• [11]Miyazawa A, Ako J, Hongo Y, Hur SH, Tsujino I, Courtney BK, et al.: Comparison of vascular response to zotarolimus-eluting stent versus sirolimus-eluting stent: intravascular ultrasound results from ENDEAVOR III. Am Heart J 2008, 155:108-113.
• [12]Pinto Slottow TL, Waksman R: Overview of the 2007 Food and Drug Administration Circulatory System Devices Panel meeting on the endeavor zotarolimus-eluting coronary stent. Circulation 2008, 117:1603-1608.
• [13]Lewis AL, Tolhurst LA, Stratford PW: Analysis of a phosphorylcholine-based polymer coating on a coronary stent pre- and post-implantation. Biomaterials 2002, 23:1697-1706.
• [14]Maeng M, Jensen LO, Falk E, Andersen HR, Thuesen L: Negative vascular remodelling after implantation of bioabsorbable magnesium alloy stents in porcine coronary arteries: a randomised comparison with bare-metal and sirolimus-eluting stents. Heart 2009, 95:241-246.
• [15]Maeng M, Jensen LO, Galloe AM, Thayssen P, Christiansen EH, Hansen KN, et al.: Comparison of the sirolimus-eluting versus paclitaxel-eluting coronary stent in patients with diabetes mellitus: the diabetes and drug-eluting stent (DiabeDES) randomized angiography trial. Am J Cardiol 2009, 103:345-349.
• [16]Jensen LO, Maeng M, Thayssen P, Christiansen EH, Hansen KN, Galloe A, et al.: Neointimal hyperplasia after sirolimus-eluting and paclitaxel-eluting stent implantation in diabetic patients: The Randomized Diabetes and Drug-Eluting Stent (DiabeDES) Intravascular Ultrasound Trial. Eur Heart J 2008, 29:2733-2741.
• [17]Dibra A, Kastrati A, Mehilli J, Pache J, Sch hlen H, von Beckerath N, et al.: Paclitaxel-eluting or Sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med 2005, 353:663-670.
• [18]Joner M, Nakazawa G, Finn AV, Quee SC, Coleman L, Acampado E, et al.: Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol 2008, 52:333-342.
• [19]Nakazawa G, Finn AV, John MC, Kolodgie FD, Virmani R: The significance of preclinical evaluation of sirolimus-, paclitaxel-, and zotarolimus-eluting stents. Am J Cardiol 2007, 100:36M-44M.
• [20]Sørensen HT, Lash TL, Rothman KJ: Beyond randomized controlled trials: a critical comparison of trials with nonrandomized studies. Hepatology 2006, 44:1075-1082.
• [21]Jensen LO, Maeng M, Kaltoft A, Thayssen P, Hansen HH, Bottcher M, et al.: Stent thrombosis, myocardial infarction, and death after drug-eluting and bare-metal stent coronary interventions. J Am Coll Cardiol 2007, 50:463-470.
• [22]Mauri L, Hsieh WH, Massaro JM, Ho KK, D’Agostino R, Cutlip DE: Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007, 356:1020-1029.
• [23]Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A: Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation 1994, 90:583-612.
• [24]Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40:373-383.
• [25]Rasmussen K, Maeng M, Kaltoft A, Thayssen P, Kelbaek H, Tilsted HH, et al.: Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial. Lancet 2010, 375:1090-1099.
• [26]Kim JS, Jang IK, Kim JS, Kim TH, Takano M, Kume T, et al.: Optical coherence tomography evaluation of zotarolimus-eluting stents at 9-month follow-up: comparison with sirolimus-eluting stents. Heart 2009, 95:1907-1912.
• [27]Kandzari DE, Leon MB, Popma JJ, Fitzgerald PJ, O’Shaughnessy C, Ball MW, et al.: Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol 2006, 48:2440-2447.
• [28]Frobert O, Lagerqvist B, Carlsson J, Lindback J, Stenestrand U, James SK: Differences in restenosis rate with different drug-eluting stents in patients with and without diabetes mellitus: a report from the SCAAR (Swedish Angiography and Angioplasty Registry). J Am Coll Cardiol 2009, 53:1660-1667.
• [29]Park DW, Kim YH, Yun SC, Kang SJ, Lee SW, Lee CW, et al.: Comparison of zotarolimus-eluting stents with sirolimus- and paclitaxel-eluting stents for coronary revascularization: the ZEST (comparison of the efficacy and safety of zotarolimus-eluting stent with sirolimus-eluting and paclitaxel-eluting stent for coronary lesions) randomized trial. J Am Coll Cardiol 2010, 56:1187-1195.
• [30]Lee CW, Park DW, Lee SH, Kim YH, Hong MK, Kim JJ, et al.: Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction. Am J Cardiol 2009, 104:1370-1376.
• [31]Byrne RA, Mehilli J, Iijima R, Schulz S, Pache J, Seyfarth M, et al.: A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents. Eur Heart J 2009, 30:923-931.
• [32]Mauri L, Orav EJ, Kuntz RE: Late loss in lumen diameter and binary restenosis for drug-eluting stent comparison. Circulation 2005, 111:3435-3442.
• [33]Mauri L, Orav EJ, Candia SC, Cutlip DE, Kuntz RE: Robustness of late lumen loss in discriminating drug-eluting stents across variable observational and randomized trials. Circulation 2005, 112:2833-2839.
• [34]Pocock SJ, Lansky AJ, Mehran R, Popma JJ, Fahy MP, Na Y, et al.: Angiographic surrogate end points in drug-eluting stent trials: a systematic evaluation based on individual patient data from 11 randomized, controlled trials. J Am Coll Cardiol 2008, 51:23-32.
• [35]Serruys PW, Silber S, Garg S, van Geuns RJ, Richardt G, Buszman PE, et al.: Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med 2010, 363:136-146.
• [36]Jensen LO, Maeng M, Thayssen P, Kaltoft A, Tilsted HH, Lassen JF, et al.: Long-term outcomes after percutaneous coronary intervention in patients with and without diabetes mellitus in Western Denmark. Am J Cardiol 2010, 105:1513-1519.
• [37]Briguori C, Airoldi F, Visconti G, Focaccio A, Caiazzo G, Golia B, et al.: Novel Approaches for Preventing or Limiting Events in Diabetic Patients (Naples-Diabetes) Trial: A Randomized Comparison of 3 Drug-Eluting Stents in Diabetic Patients. Circ Cardiovasc Interv 2011, 4:121-129.